Evidence of P-glycoprotein sequence diversity in cyathostominsDROGEMULLER, Michaela; SCHNIEDER, T; VON SAMSON-HIMMELSTIERNA, G et al.The Journal of parasitology. 2004, Vol 90, Num 5, pp 998-1003, issn 0022-3395, 6 p.Article

Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforinWANG, Er-Jia; BARECKI-ROACH, Mary; JOHNSON, William W et al.Journal of pharmacy and pharmacology. 2004, Vol 56, Num 1, pp 123-128, issn 0022-3573, 6 p.Article

Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein effluxSHAN, Yong-Qiang; GANG REN; JIANG, Jian-Dong et al.Metabolism, clinical and experimental. 2013, Vol 62, Num 3, pp 446-456, issn 0026-0495, 11 p.Article

New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitorsZHOU, Xiao-Fei; LINPING ZHANG; TSENG, Elaine et al.Drug metabolism and disposition. 2005, Vol 33, Num 3, pp 321-328, issn 0090-9556, 8 p.Article

Anthelmintics Are Substrates and Activators of Nematode P GlycoproteinKERBOEUF, Dominique; GUEGNARD, Fabrice.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 5, pp 2224-2232, issn 0066-4804, 9 p.Article

P-glycoprotein function in the elderlyBRENNER, Stefanie S; KLOTZ, Ulrich.European journal of clinical pharmacology. 2004, Vol 60, Num 2, pp 97-102, issn 0031-6970, 6 p.Article

Characterization of a new antibody raised against the NH₂ terminus of P-glycoproteinRAO, Prema S; GOVINDARAJAN, Rajgopal; MALLYA, Kavita B et al.Clinical cancer research. 2005, Vol 11, Num 16, pp 5833-5839, issn 1078-0432, 7 p.Article

Identification of P-Glycoprotein Inhibitors in Contaminated Freshwater SedimentsZAJA, Roko; TERZIC, Senka; SENTA, Ivan et al.Environmental science & technology. 2013, Vol 47, Num 9, pp 4813-4821, issn 0013-936X, 9 p.Article

High Levels of P-Glycoprotein Activity in Human Lymphocytes in the First 6 Months of LifeGIRAUD, C; DECLEVES, X; SCHERRMANN, J. M et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 3, pp 289-295, issn 0009-9236, 7 p.Article

Potential P-Glycoprotein-Mediated Drug-Drug Interactions of Antimalarial Agents in Caco-2 cellsOGA, Enoche F; SEKINE, Shuichi; SHITARA, Yoshihisa et al.The American journal of tropical medicine and hygiene. 2012, Vol 87, Num 1, pp 64-69, issn 0002-9637, 6 p.Article

Macelignan: A New Modulator of P-Glycoprotein in Multidrug-Resistant Cancer CellsYOUNG BIN IM; HA, Iiho; KEON WOOK KANG et al.Nutrition and cancer. 2009, Vol 61, Num 4, pp 538-543, issn 0163-5581, 6 p.Article

Functional role of P-glycoprotein in the human blood-placental barrierMÖLSÄ, Melissa; HEIKKINEN, Tuija; HAKKOLA, Jukka et al.Clinical pharmacology and therapeutics. 2005, Vol 78, Num 2, pp 123-131, issn 0009-9236, 9 p.Article

Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetateCHENG WANG; ZHANG, Jin-Xia; SHEN, Xiao-Ling et al.Biochemical pharmacology. 2004, Vol 68, Num 5, pp 843-855, issn 0006-2952, 13 p.Article

P-Selectin Glycoprotein Ligand-1 Contributes to Wound Healing Predominantly as a P-Selectin Ligand and Partly as an E-Selectin LigandTOMITA, Hajime; IWATA, Yohei; TAKENAKA, Motoi et al.Journal of investigative dermatology. 2009, Vol 129, Num 8, pp 2059-2067, issn 0022-202X, 9 p.Article

Evaluation of the Impact of P-Glycoprotein (P-gp) Drug Efflux Transporter Blockade on the Systemic and Ocular Disposition of P-gp SubstrateSENTHILKUMARI, Srinivasan; VELPANDIAN, Thirumurthy; BISWAS, Nihar R et al.Journal of ocular pharmacology and therapeutics. 2008, Vol 24, Num 3, pp 290-300, issn 1080-7683, 11 p.Article

A topological substructural approach for the prediction of P-glycoprotein substratesCABRERA, Miguel Angel; GONZALEZ, Isabel; FERNANDEZ, Carlos et al.Journal of pharmaceutical sciences. 2006, Vol 95, Num 3, pp 589-606, issn 0022-3549, 18 p.Article

Modulation of P-glycoprotein expression in hyperthyroid rat tissuesNISHIO, Naoki; KATSURA, Toshiya; ASHIDA, Kayoko et al.Drug metabolism and disposition. 2005, Vol 33, Num 11, pp 1584-1587, issn 0090-9556, 4 p.Article

Clinical pharmacology of P-glycoprotein and related transporters. Part IIWOODCOCK, B. G; PREISS, R.International journal of clinical pharmacology and therapeutics. 2000, Vol 38, Num 4, issn 0946-1965, 62 p.Serial Issue

Furanocoumarin Derivatives in Kampo Extract Medicines Inhibit Cytochrome P450 3A4 and P-GlycoproteinIWANAGA, Kazunori; HAYASHI, Manami; HAMAHATA, Yukimi et al.Drug metabolism and disposition. 2010, Vol 38, Num 8, pp 1286-1294, issn 0090-9556, 9 p.Article

Interaction between Topically and Systemically Coadministered P-Glycoprotein Substrates/Inhibitors: Effect on Vitreal KineticsHIPPALGAONKAR, Ketan; SRIRANGAM, Ramesh; AVULA, Bharathi et al.Drug metabolism and disposition. 2010, Vol 38, Num 10, pp 1790-1797, issn 0090-9556, 8 p.Article

20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In Vitro and In Vivo: A Case for Herb-Drug InteractionsJINGWEI ZHANG; FANG ZHOU; YING PENG et al.Drug metabolism and disposition. 2010, Vol 38, Num 12, pp 2179-2187, issn 0090-9556, 9 p.Article

Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions?DECLEVES, Xavier; NIEL, Elisabeth; DEBRAY, Marcel et al.Toxicology and applied pharmacology. 2006, Vol 217, Num 2, pp 153-160, issn 0041-008X, 8 p.Article

Computational models for predicting substrates or inhibitors of P-glycoproteinLEI CHEN; YOUYONG LI; HUIDONG YU et al.Drug discovery today. 2012, Vol 17, Num 7-8, pp 343-351, issn 1359-6446, 9 p.Article

Evaluation of In Vivo P-Glycoprotein Phenotyping Probes: A Need for ValidationMA, Joseph D; TSUNODA, Shirley M; BERTINO, Joseph S et al.Clinical pharmacokinetics. 2010, Vol 49, Num 4, pp 223-237, issn 0312-5963, 15 p.Article

Uptake/Efflux Transport of Tramadol Enantiomers and O -Desmethyl-Tramadol: Focus on P-GlycoproteinKANAAN, Mouna; DAALI, Youssef; DAYER, Pierre et al.Basic & clinical pharmacology & toxicology (Print). 2009, Vol 105, Num 3, pp 199-206, issn 1742-7835, 8 p.Article